HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA meetings

This article was originally published in The Rose Sheet

Executive Summary

Agency's "Vision 2006 - A Conversation with the American Public" will comprise three public meetings to be held Sept. 13 in Miami, Fla., Nov. 2 in Cambridge, Mass., and Nov. 30 in Phoenix, Ariz., according to an Aug. 16 Federal Register 1notice. Meetings will allow FDA to update consumers on agency programs, obtain consumer opinion and encourage public discussion, and will be attended by Commissioner Lester Crawford and "all of the agency's top leadership," FDA says. Feedback will be used to "evaluate and to propose modifications, if necessary, to our programs and activities," agency notes. FDA lists a number of questions it plans to ask the public, such as "What additional steps can FDA take to improve its communication with consumers and build on your confidence in its activities and mission?" Comments on discussion topics also are sought by Nov. 30...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS013288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel